Compare ELWT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELWT | SCLX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | 34 | 34 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5M | 52.5M |
| IPO Year | N/A | N/A |
| Metric | ELWT | SCLX |
|---|---|---|
| Price | $7.16 | $9.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 47.5K | ★ 118.9K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.81 | $122.52 |
| Revenue Next Year | $70.70 | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.11 | $4.20 |
| 52 Week High | $9.72 | $34.27 |
| Indicator | ELWT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 62.83 |
| Support Level | $6.61 | $7.73 |
| Resistance Level | $7.36 | $9.44 |
| Average True Range (ATR) | 0.69 | 0.97 |
| MACD | 0.12 | 0.25 |
| Stochastic Oscillator | 53.28 | 79.51 |
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.